TP53 and neoplasm: Genetic testing revealed HER2 exon 20 and TP53 mutations, prompting a shift to two cycles of neoadjuvant T-DXd, which reduced the tumor size to 2.0 × 2.4 × 1.0 cm with substantially lowered metabolic activity (SUVmax 1.38).